“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...

GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...

A Dutch court ruled on Wednesday that billionaire and global vaccine proponent, Bill Gates, must stand trial in the ...

An agency panel recommended lowering the age for routine vaccination from 65 to 50, boosting the revenue outlook for multiple ...

The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...

J.P. Morgan analyst Chris Schott maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $30.00. The ...

On Wednesday, the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) ...

Advisory Committee on Immunization Practice (ACIP) voted to expand its recommendation for the use of certain pneumococcal ...

“RSV represents a significant threat to younger adults with certain chronic conditions. After decades of vaccine research by the scientific community and Pfizer, we now have the opportunity to help ...

Further experiments in a mouse model suggested that the antibodies were first being circulated in the blood, before migrating ...

Stanley Laman Group Ltd. cut its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 3.2% in the 3rd quarter, Holdings ...

Elevated Capital Advisors LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 6.7% during the 3rd ...